Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Dexamethasone
/ administration & dosage
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Multiple Myeloma
/ diagnosis
Oligopeptides
/ administration & dosage
Prognosis
Recurrence
Retreatment
Survival Analysis
Treatment Outcome
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
21
03
2019
accepted:
09
05
2019
pubmed:
23
5
2019
medline:
14
1
2020
entrez:
23
5
2019
Statut:
ppublish
Résumé
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy for frontline treatment of multiple myeloma has resulted in a need for effective regimens for lenalidomide-refractory patients. This phase 1b study evaluated daratumumab plus carfilzomib and dexamethasone (D-Kd) in patients with RRMM after 1 to 3 prior lines of therapy, including bortezomib and an immunomodulatory drug; lenalidomide-refractory patients were eligible. Carfilzomib- and daratumumab-naïve patients (n = 85) received carfilzomib weekly on days 1, 8, and 15 of each 28-day cycle (20 mg/m
Identifiants
pubmed: 31113777
pii: S0006-4971(20)42370-5
doi: 10.1182/blood.2019000722
pmc: PMC6676132
doi:
Substances chimiques
Antibodies, Monoclonal
0
Oligopeptides
0
daratumumab
4Z63YK6E0E
carfilzomib
72X6E3J5AR
Dexamethasone
7S5I7G3JQL
Banques de données
ClinicalTrials.gov
['NCT01998971']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-431Informations de copyright
© 2019 by The American Society of Hematology.
Références
Leukemia. 2012 Jan;26(1):149-57
pubmed: 21799510
Lancet Oncol. 2018 Jul;19(7):953-964
pubmed: 29866475
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
Clin Cancer Res. 2016 Nov 15;22(22):5443-5452
pubmed: 28151712
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104
pubmed: 27028734
N Engl J Med. 2014 Sep 4;371(10):906-17
pubmed: 25184863
MAbs. 2015;7(2):311-21
pubmed: 25760767
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Br J Haematol. 2019 May;185(3):492-502
pubmed: 30828799
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
JAMA Oncol. 2018 Mar 8;4(3):e174519
pubmed: 29285538
Lancet Oncol. 2016 Jan;17(1):27-38
pubmed: 26671818
Haematologica. 2018 Dec;103(12):2079-2087
pubmed: 30237264
Cytometry A. 2019 Mar;95(3):279-289
pubmed: 30536810
Blood Adv. 2018 Jul 10;2(13):1633-1644
pubmed: 29991494
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Blood. 2011 May 5;117(18):4691-5
pubmed: 21292775
Clin Pharmacokinet. 2017 Aug;56(8):915-924
pubmed: 27896689
Blood. 2017 Aug 24;130(8):963-973
pubmed: 28679737
Leukemia. 2017 Jan;31(1):115-122
pubmed: 27491641
Lancet Oncol. 2013 Oct;14(11):1055-1066
pubmed: 24007748
JAMA Oncol. 2018 Oct 1;4(10):1389-1397
pubmed: 30098165
N Engl J Med. 2018 Nov 8;379(19):1811-1822
pubmed: 30403938
J Immunol. 2016 Aug 1;197(3):807-13
pubmed: 27316683
Haematologica. 2018 Dec;103(12):2088-2096
pubmed: 30237262
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Blood. 2016 Jul 21;128(3):384-94
pubmed: 27222480
Lancet Oncol. 2019 Jun;20(6):781-794
pubmed: 31097405